Literature DB >> 26798440

Novel therapeutic agents in the treatment of metastatic colorectal cancer.

Sachin Gopalkrishna Pai1, Jyotsna Fuloria1.   

Abstract

Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers (mCRC) leading to a significant improvement in five-year survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of cancer and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article we will discuss various targeted therapies in the management of mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well.

Entities:  

Keywords:  Anti-angiogenesis inhibitors; Epidermal growth factor receptor inhibitors; Metastatic colorectal cancer; Molecular targeted drugs; Novel therapeutic agents

Year:  2016        PMID： 26798440      PMCID： PMC4714150          DOI： 10.4251/wjgo.v8.i1.99

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  32 in total

1.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

2.  Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.

Authors:  J Randolph Hecht; Edith Mitchell; Marcus A Neubauer; Howard A Burris; Paul Swanson; Timothy Lopez; Glenn Buchanan; Maureen Reiner; Jennifer Gansert; Jordan Berlin
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

4.  Maximal expiratory flow and lung volume changes associated with exercise-induced asthma in children and the effect of breathing a low-density gas mixture.

Authors:  S R Benatar; P Hönig
Journal:  Clin Sci Mol Med       Date:  1974-03

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

6.  Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

Authors:  D Koeberle; D C Betticher; R von Moos; D Dietrich; P Brauchli; D Baertschi; K Matter; R Winterhalder; M Borner; S Anchisi; P Moosmann; A Kollar; P Saletti; A Roth; M Frueh; M Kueng; R A Popescu; S Schacher; V Hess; R Herrmann
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

Authors:  D Helbling; G Bodoky; O Gautschi; H Sun; F Bosman; B Gloor; R Burkhard; R Winterhalder; A Madlung; D Rauch; P Saletti; L Widmer; M Borner; D Baertschi; P Yan; J Benhattar; E O Leibundgut; S Bougel; D Koeberle
Journal:  Ann Oncol       Date:  2012-11-08       Impact factor: 32.976

10.  Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Authors:  Alain Hendlisz; Amélie Deleporte; Caroline Vandeputte; Nicolas Charette; Marianne Paesmans; Thomas Guiot; Camilo Garcia; Patrick Flamen
Journal:  BMJ Open       Date:  2015-03-09       Impact factor: 2.692
View more
  11 in total

1.  Immunoglobulin E induces colon cancer cell apoptosis via enhancing cyp27b1 expression.

Authors:  Zhen-Shi Ye; Li-Na Fan; Lin Wang; Bin Yang; Li-Feng Wang; Yuan-Sheng Liu; Su-Na Ji; Hong-Zhi Xu; Chuan-Xing Xiao
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 2.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

3.  Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Amr Mohamed Mohamed; Osama Adnan Kensara; Jawwad Ahmad; Shakir Idris
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

Review 4.  Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews.

Authors:  Hossein Mashhadi Abdolahi; Ali Sarabi Asiabar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Aziz Rezapour
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Jan-Mar

5.  MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX.

Authors:  I Kiss; J Mlčochová; K Součková; P Fabian; A Poprach; J Halamkova; M Svoboda; R Vyzula; O Slaby
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

6.  TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells.

Authors:  Jeffrey Q Nguyen; Rosalyn B Irby
Journal:  Cancer Biol Ther       Date:  2016-11-10       Impact factor: 4.742

7.  LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics.

Authors:  Qian Yao; Yu An; Wei Hou; Ya-Nan Cao; Meng-Fei Yao; Ning-Ning Ma; Lin Hou; Hong Zhang; Hai-Jing Liu; Bo Zhang
Journal:  Oncotarget       Date:  2017-11-30

8.  Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling.

Authors:  Omar Al-Obeed; Adila Salih El-Obeid; Sabine Matou-Nasri; Mansoor-Ali Vaali-Mohammed; Yazeid AlHaidan; Mohammed Elwatidy; Hamad Al Dosary; Zeyad Alehaideb; Khayal Alkhayal; Adil Haseeb; James McKerrow; Rehan Ahmad; Maha-Hamadien Abdulla
Journal:  Cancer Cell Int       Date:  2020-04-16       Impact factor: 5.722

Review 9.  Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer.

Authors:  Osman Ali; Mazen Tolaymat; Shien Hu; Guofeng Xie; Jean-Pierre Raufman
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

Review 10.  Guanylyl cyclase C signaling axis and colon cancer prevention.

Authors:  Amanda M Pattison; Dante J Merlino; Erik S Blomain; Scott A Waldman
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.